1. Pfizer's fundamentals are improving with solid Q3 earnings and upgraded 2024 guidance; 2. The stock is undervalued with a 32% upside potential based on a $33.39 intrinsic value per share; 3. Despite recent share price weakness, Pfizer offers a compelling forward dividend yield supported by strong revenue growth and aggressive R&D spending.